Dapagliflozin to prevent atrial fibrillation return after ablation
Part of Heart & circulation clinical trials.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have type 2 diabetes or heart failure
- You must have confirmed atrial fibrillation (irregular heartbeat)
- This must be your first catheter ablation (procedure to fix the heartbeat)
- You cannot be pregnant, breastfeeding, or planning pregnancy
- You cannot have a urinary tract infection, allergy to dapagliflozin, or severe kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This study tests whether a daily medication called dapagliflozin (usually used for diabetes) can improve the success of rhythm control (treatments that bring your heartbeat back to normal) in people with recent atrial fibrillation. If you join, you would receive either the study drug or a placebo along with standard care.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.